Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Sci (Lond) ; 132(18): 2071-2085, 2018 09 28.
Artículo en Inglés | MEDLINE | ID: mdl-29959186

RESUMEN

Congenital urinary tract obstruction is one of the most frequent malformations in fetuses or neonates, which usually causes profound impairment of renal function including reductions in both glomerular filtration rate (GFR) and tubular handling of water and solutes. Although obstruction can be released by surgical operation, the child will suffer from diuresis for sometime. It has been reported that erythropoietin (EPO) could prevent the down-regulation of aquaporin-2 (AQP2) and urinary-concentrating defects induced by renal ischemia/reperfusion (I/R) injury. However, whether EPO could promote the recovery of renal function and AQP2 expression after releasing of ureteral obstruction has not been reported yet. The purposes of the present study were to investigate the effects of EPO on renal function and AQP2 expression after release of bilateral ureteral obstruction (BUO-R) in rats. The results showed that EPO could promote interleukin (IL) 10 (IL-10) expression; inhibit tumor necrosis factor-α (TNF-α), IL-6, and inducible nitric oxide synthase (iNOS) expressions; reduce the fractional excretion of sodium (FENa) and plasma creatinine (CREA) and urea; and promote the recovery of water and salt handling and AQP2 expression in BUO-R rats, especially in the high dose of EPO-treated group rats. In conclusion, EPO could promote the recovery of renal function and AQP2 expression in BUO-R rats, which may partially associate with its anti-inflammation effect.


Asunto(s)
Modelos Animales de Enfermedad , Eritropoyetina/farmacología , Riñón/efectos de los fármacos , Obstrucción Ureteral/fisiopatología , Animales , Acuaporina 2/genética , Acuaporina 2/metabolismo , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Riñón/metabolismo , Riñón/fisiopatología , Masculino , Sustancias Protectoras/farmacología , Ratas Sprague-Dawley , Daño por Reperfusión/metabolismo , Daño por Reperfusión/fisiopatología , Obstrucción Ureteral/genética , Obstrucción Ureteral/metabolismo
2.
Acta Paediatr ; 103(10): e450-3, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24912545

RESUMEN

AIM: The neonatal period is critical in bladder development, encompassing the transition from foetal bladder contractions to voluntary infant urination. The aim of this study was to investigate different voiding parameters between male and female newborn infants. METHODS: We studied 102 healthy, single birth newborn infants - 54 preterm and 48 full-term - without lower urinary tract diseases, hospitalised in the neonatal intensive care unit from March 2011 to March 2012. Free voiding was observed from 9 a.m. to 9 p.m., and the free voiding parameters and fluid intake were recorded and compared between male and female newborn infants using the Student's t-test and chi-square test. RESULTS: Male preterm newborns demonstrated larger mean postvoid residual volumes and lower bladder emptying rates than female preterm newborns (p < 0.05), and male full-term newborns had lower bladder emptying rates than female full-term newborns (p < 0.05). The bladder emptying rates of newborns defecating simultaneously with voiding were not statistically different between males and females of the same gestational age (p > 0.05). CONCLUSION: Male newborns were more likely to have larger postvoid residual volumes than females, and defecating simultaneously with voiding may promote bladder emptying in male newborns.


Asunto(s)
Recién Nacido/fisiología , Caracteres Sexuales , Micción , Femenino , Humanos , Recien Nacido Prematuro/fisiología , Masculino
3.
Chronic Dis Transl Med ; 5(1): 44-52, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30993263

RESUMEN

OBJECTIVE: To explore genes potentially co-expressed with cyclin E in gastric cancer and discover possible targets for gastric cancer treatment. METHODS: The Cancer Genome Atlas (TCGA) stomach adenocarcinoma sequencing data were used to predict genes co-expressed with cyclin E. Co-expression genes predicted by cBioPortal online analysis with Pearson correlation coefficient ≥0.4 were analyzed by gene ontology (GO) enrichment annotation using the PANTHER online platform (Ver. 7). Interactions between proteins encoded by these genes were analyzed using the STRING online platform (Ver. 10.5) and Cytoscape software (Ver. 3.5.1). Genes displaying a high degree of connection were analyzed by transcription factor enrichment prediction using FunRich software (Ver. 3). The significant transcription factor and cyclin E expression levels and their impact on gastric cancer progression were analyzed by Western blotting and Kaplan-Meier survival curve analysis. RESULTS: After filtering the co-expression gene prediction results, 78 predicted genes that included 73 protein coding genes and 5 non-coding genes with Pearson correlation coefficient ≥0.4 were selected. The expressions of the genes were considered to be correlated with cyclin E expression. Among the 78 genes co-expressed with cyclin E, 19 genes at the central of the regulatory network associated with cyclin E were discovered. Nuclear transcription factor Y subunit alpha (NF-YA) was identified as a significant transcription factor associated with cyclin E co-expressing genes. Analysis of specimen donors' clinical records revealed that high expression of NF-YA tended to be associated with increased cyclin E expression. The expression of both was associated with progression of gastric cancer. Western blotting results showed that compared with normal tissues, NF-YA and cyclin E were highly expressed in tumor tissues (P < 0.001). Survival curve analysis clearly demonstrated relatively poor overall survival of gastric cancer patients with high cyclin E or high NF-YA expression level, compared to patients with low cyclin E or NF-YA expression (P < 0.05). CONCLUSIONS: NF-YA may promote gastric cancer progression by increasing the transcription of cyclin E and other cell cycle regulatory genes. NF-YA might be a potential therapeutically useful prognostic factor for gastric cancer.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA